Table S1. Effects of BLM or BAPN at indicated concentration on LO mRNA expression.

		LO gene		β-actin		Qty (LO)/Qty (β-actin)	Mean±SD	P
Samples	Repeat	Ct	Qty	Ct	Qty
Control	1	27.52	2.62×103	16.30	1.39×107	1.88×10−4
	2	27.51	4.70×103	17.88	1.24×107	3.79×10−4	2.2±1.4 (×10−4)
	3	29.34	1.27×103	17.77	1.34×107	0.95×10−4
BLM (3 μg/mL)	1	27.03	3.86×103	20.69	4.22×106	9.10×10−4
	2	27.93	3.41×103	20.78	1.83×106	18.60×10−4	12.1±5.6 (×10−4)b	0.041
	3	28.39	2.50×103	20.12	2.83×106	8.70×10−4
BLM (10 μg/mL)	1	22.46	1.45×104	15.10	3.63×107	3.90×10−4
	2	23.65	7.59×104	14.75	9.85×107	7.70×10−4	7.7±3.7 (×10−4)	0.078
	3	23.44	8.84×104	15.15	7.64×107	11.40×10−4
BLM (30 μg/mL)	1	34.35	34.47	20.36	4.63×106	7.44×10−6
	2	34.76	25.66	20.21	2.76×106	9.30×10−6	10.6±3.9 (×10−6)	0.066
	3	33.23	68.01	20.68	4.56×106	14.91×10−6
BAPN (100 μmol/L)	1	20.10	4.86×105	13.99	8.72×107	5.57×10−3
	2	21.40	3.83×105	14.11	1.5×108	2.55×10−3	36.1±16.9 (×10−4)b	0.026
	3	21.81	2.86×105	14.65	1.05×108	2.72×10−3

Note: The mRNA expression of LO was evaluated by real-time RT-PCR. β-actin was used as an internal control. ^bP<0.05 compared with control. BLM, bleomycin; BAPN, beta-aminopropionitrile; LO, lysyl oxidase.